NASDAQ: ATHE - Alterity Therapeutics Limited

半年間の収益性: +73%
配当利回り: 0.00%
セクタ: Healthcare

プロモーションスケジュール Alterity Therapeutics Limited

詳細なスケジュール 簡易グラフ
Financial Markets by TradingView

会社について Alterity Therapeutics Limited

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease.

さらに詳しく
It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
比較リストに追加
ウォッチリストに追加
ポートフォリオに追加
価格通知を追加

IPO date 2002-09-05
ISIN US02155X1063
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета aud
Сайт https://alteritytherapeutics.com
Цена ао 1.45
1日あたりの価格変動: -0.2858% (3.149)
週ごとの価格変動: +42.73% (2.2)
月ごとの料金変更: +188.07% (1.09)
3ヶ月間の価格変動: +136.98% (1.325)
半年間の価格変動: +73% (1.815)
年間の価格変動: +26.1% (2.49)
3年間の価格推移: +256.01% (0.882)
5年間の価格推移: +204.85% (1.03)
10年間の価格推移: 0% (3.14)
年初からの価格変動: +193.46% (1.07)
すべてのパラメータ

過小評価

名前 意味 学年
P/S 4.09 4
P/BV 1.19 9
P/E 0 0
EV/EBITDA -0.2025 0
合計: 5.38

効率

名前 意味 学年
ROA, % -82.18 0
ROE, % -104.47 0
合計: 0

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0

義務

名前 意味 学年
Debt/EBITDA -0.0081 10
合計: 9.6

成長の衝動

名前 意味 学年
収益性 Revenue, % 876.58 10
収益性 Ebitda, % 89.99 9
収益性 EPS, % 31034.18 10
合計: 8.6
さらに詳しく

機関 音量 共有, %
Morgan Stanley 51485 0.7
Bank of Montreal/Can/ 14907 0.2
Twin Lakes Capital Management, LLC 5925 0.08
Providence Capital Advisors, LLC 200 0
Coppell Advisory Solutions, LLC 149 0
Osaic Holdings Inc 81 0
Sugarloaf Wealth Management, LLC 33 0
Steward Partners Investment Advisory, LLC 6 0



スーパーバイザー 役職 支払い 生年
Mr. Geoffrey Paul Kempler B.Sc. Co-Founder & Non-Executive Chairman 207.52k 1955 (70 年)
Dr. David A. Stamler M.D. Chief Executive Officer 613.33k 1961 (64 年)
Dr. Rudolph Emile Tanzi Ph.D. Chief Scientific Advisor and Member of Research & Development Advisory Board N/A 1959 (66 年)
Dr. Robert Cherny Head of Research N/A
Mr. Phillip Allen Hains BBus(Acc), C.A., M.B.A. CFO & Company Secretary N/A 1959 (66 年)
Dr. Steven D. Targum M.D. Chief Medical Advisor

住所: Australia, Melbourne, 350 Collins Street - Googleマップで開く, Yandexマップを開く
Webサイト: https://alteritytherapeutics.com